Biomarker: EGFR

Gefitinib (Iressa)

Targeted TherapyApproved for: NSCLCBiomarker: EGFR Gefitinib (Iressa) approved Targeted Therapy for non-small cell lung cancer (NSCLC) that has metastasized (spread to other parts of the body). It is used as first-line treatment in patients whose tumors have certain EGFR...
Read More
|
June 1, 2021
|
Treatment

Erlotinib (Tarceva)

Targeted TherapyApproved for: NSCLCBiomarker: EGFR Erlotinib (Tarceva) approved Targeted Therapy for Non-small cell lung cancer (NSCLC) that is metastatic and has certain EGFR gene mutations. It may be used: As first-line therapy. In patients on maintenance therapy or whose...
Read More
|
June 1, 2021
|
Treatment

Ramucirumab (Cyramza)

Targeted TherapyApproved for: NSCLCBiomarker: EGFR, ALK Ramucirumab (Cyramza) is a FDA-approved Targeted Therapy for non-small cell lung cancer (NSCLC) with the biomarker EGFR or ALK that has metastasized. It is used: With docetaxel in patients whose disease has gotten worse...
Read More
|
May 31, 2021
|
Treatment

Afatinib (Gilotrif)

Targeted TherapyApproved for: NSCLCEGFR Afatinib (Gilotrif) is a FDA-approved Targeted Therapy for Non-small cell lung cancer (NSCLC) that has metastasized (spread to other parts of the body). It is used: As first-line treatment in patients with tumors that have...
Read More
|
May 30, 2021
|
Treatment

Osimertinib (Tagrisso)

Targeted TherapyApproved for: NSCLCEGFR Osimertinib (Tagrisso) is a FDA-approved targeted therapy for non-small cell lung cancer (NSCLC) in adults whose tumors have certain EGFR gene mutations. It is used: As adjuvant therapy after surgery to remove the tumor, As...
Read More
|
May 30, 2021
|
Treatment

Dacomitinib (Vizimpro)

Targeted TherapyApproved for: NSCLCBiomarker: EGFR Dacomitinib (Vizimpro) is a FDA-approved treatment for Non-small cell lung cancer (NSCLC) that has metastasized (spread to other parts of the body). It is used as first-line treatment in patients whose tumors have certain...
Read More
|
May 27, 2021
|
Treatment

Ramucirumab (Cyramza)

Targeted TherapyApproved for: NSCLCBiomarker: EGFR, ALK Ramucirumab (Cyramza) is a FDA-approved treatment for non-small cell lung cancer (NSCLC) that has metastasized. It is used: With erlotinib hydrochloride as first-line therapy in patients whose disease has certain mutations in the...
Read More
|
March 19, 2021
|
Treatment